Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Sold by Algert Global LLC

Algert Global LLC lessened its stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP by 33.9% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 128,013 shares of the biotechnology company's stock after selling 65,791 shares during the period. Algert Global LLC owned 0.09% of Aurinia Pharmaceuticals worth $938,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of the stock. Charles Schwab Investment Management Inc. raised its position in shares of Aurinia Pharmaceuticals by 13.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 744,050 shares of the biotechnology company's stock worth $5,454,000 after purchasing an additional 89,940 shares during the last quarter. Intech Investment Management LLC purchased a new stake in Aurinia Pharmaceuticals during the 3rd quarter valued at about $262,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Aurinia Pharmaceuticals during the 3rd quarter valued at about $3,330,000. Segall Bryant & Hamill LLC grew its stake in Aurinia Pharmaceuticals by 1.6% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 562,775 shares of the biotechnology company's stock valued at $4,125,000 after acquiring an additional 9,031 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its stake in Aurinia Pharmaceuticals by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 27,502 shares of the biotechnology company's stock valued at $202,000 after acquiring an additional 10,700 shares in the last quarter. Institutional investors and hedge funds own 36.83% of the company's stock.

Aurinia Pharmaceuticals Trading Up 0.1 %

Shares of Aurinia Pharmaceuticals stock traded up $0.01 during mid-day trading on Friday, hitting $8.86. The stock had a trading volume of 771,994 shares, compared to its average volume of 1,598,603. The firm has a 50-day moving average of $7.60 and a two-hundred day moving average of $6.47. Aurinia Pharmaceuticals Inc. has a 12-month low of $4.71 and a 12-month high of $9.74. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. The firm has a market cap of $1.27 billion, a P/E ratio of -59.07 and a beta of 1.45.

Insider Activity

In other news, Director Jeffrey Allen Bailey sold 4,557 shares of the company's stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $8.43, for a total value of $38,415.51. Following the transaction, the director now directly owns 13,356 shares in the company, valued at approximately $112,591.08. This represents a 25.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 4.30% of the company's stock.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. HC Wainwright reaffirmed a "buy" rating and set a $13.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Friday, September 6th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $10.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Monday, September 16th. Finally, StockNews.com raised shares of Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, November 8th. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Buy" and a consensus price target of $10.00.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.